Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study that determines a tolerable combination of sorafenib, when given
sequentially with cytarabine and clofarabine and determines the feasibility of administering
this drug combination in patients with relapsed or refractory hematologic malignancies
including acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute
lymphoblastic leukemia (ALL), infantile leukemia (both either AML and/or ALL). AML with prior
myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms, and
biphenotypic leukemia.